pay_str=and payed='1' Samedan Ltd Pharmaceutical Publishers
 
 
spacer
home > employment
EMPLOYMENT OPPORTUNITIES
  Keyword Location  
Quick search:
 
 
spacer

Are you an employer?
Submit your vacancy

Already registered employer?
Please login to your account to add a vacancy or manage your submissions.

E-mail address:

Password:

News and Press Releases

Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000

Cambridge and Wetherby, UK, 29 November 2021: Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase 1 clinical trial, ALS-6000-101, into clinical trial sites in the United States.
More info >>

 
White Papers

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement